Illumina Instruments — Total Revenue decreased by 24.1% to $120.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 7.1%, from $112.00M to $120.00M. Over 4 years (FY 2021 to FY 2025), Instruments — Total Revenue shows a downward trend with a -10.5% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase suggests strong market adoption and successful product cycles, while a decrease may indicate market saturation or a shift toward service-based models.
This metric represents the total gross revenue generated from the sale of hardware and sequencing platforms within a spe...
Comparable to hardware or capital equipment revenue lines in other life science tools or medical device companies.
ilmn_segment_instruments_total_revenue| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $194.00M | $184.00M | $195.00M | $217.00M | $193.00M | $167.00M | $151.00M | $158.00M | $197.00M | $181.00M | $167.00M | $114.00M | $120.00M | $107.00M | $159.00M | $112.00M | $101.00M | $111.00M | $158.00M | $120.00M |
| QoQ Change | — | -5.2% | +6.0% | +11.3% | -11.1% | -13.5% | -9.6% | +4.6% | +24.7% | -8.1% | -7.7% | -31.7% | +5.3% | -10.8% | +48.6% | -29.6% | -9.8% | +9.9% | +42.3% | -24.1% |
| YoY Change | — | — | — | — | -0.5% | -9.2% | -22.6% | -27.2% | +2.1% | +8.4% | +10.6% | -27.8% | -39.1% | -40.9% | -4.8% | -1.8% | -15.8% | +3.7% | -0.6% | +7.1% |